BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-245@pharmaconomics
DTSTAMP:20260707T004903Z
DTSTART;VALUE=DATE:20260918
DTEND;VALUE=DATE:20260919
SUMMARY:NUVL PDUFA — zidesamtinib
DESCRIPTION:The FDA's approval decision on zidesamtinib for ROS1-positive NSCLC is due Sep 18\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1861560/000186156026000020/nuvl-ex99_1.htm\n\nTrack it: https://www.pharmaconomics.com/e/245
URL:https://www.pharmaconomics.com/e/245
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:NUVL catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR